New 'Living Drug' trial offers hope for patients with aggressive blood cancers
NCT ID NCT06765876
Summary
This early-phase study is testing the safety of a new personalized cell therapy called CART123 for adults with advanced blood cancers that have returned or not responded to other treatments. Doctors will collect a patient's own immune cells, modify them in a lab to target cancer, and then infuse them back after a brief chemotherapy. Because the treatment carries risks, all participants must be eligible for a potential stem cell transplant as a backup plan.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES (MDS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ustav hematologie a krevni transfuze / Institute of Hematology and Blood Transfusion
RECRUITINGPrague, 12800, Czechia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.